Huahai Already Developed New Manufacturing Process for Valsartan API, Says Japan Chief after JMA Criticism on Impurity Issue

Huahai Japan Pharma President Li Xiangkui Zhejiang Huahai Pharmaceutical is taking measures to respond to a possibly cancer-causing impurity detected in its valsartan API, the Chinese company’s Japan chief said on September 4, rebutting doctors’ criticism that it is putting...read more